|
IN
THE NEWS
|
EDIT
|
Data
exclusivity may be capped at four years
Team
pharma sees many medals along the way
Three
biotech cos plan research centres in Germany |
Editorial
Skeletons
in the cupboard?
Edit Article
Generic
drug approvals in USA and Europe
|
|
OPED
|
HEALTH
NEWS
|
Schedule
M: Implementation by SSI units
While FDA is keen on introducing provisions of schedule
M effectively by January 1, 2005, small scale industry
(SSI) units in the country, by and large, are reluctant
to do so and are trying to obtain extension from time
to time from the government by giving several not fully
justifiable and weak reasons. |
Rare
blood donor registry; need of the hour
Health
insurance meet to thrash out strategy
|
|
CORPORATE
|
CLINICAL
RESEARCH
|
|
Isaar
Pharma launches peptide product for Vitiligo
Biocon
denies deaths during clinical trials of R-human insulin
Ind
Swift to tie up with US firms for contract research
Dabur
to acquire OTC brand
Ranbaxy
receives tentative USFDA approval for Gabapentin capsules
Torrent
Pharma earmarks Rs 100 crore for R&D
Wander,
Pearl Organics merge to form Wanbury
Chemgen
Pharma: Conquering dreams
|
‘Regulatory
approval is not required for comparison trial of marketed
brand and generics’
In clinical practice, it is
frequently observed that some generic brands are better
in efficacy and tolerability. We need clarification
on some of the issues for comparative clinical trials
between two brands.
|
|
HAPPENINGS
|
TECHNOLOGY
TRENDZ
|
Manipal
Academy sets up Pharmacogenomics Centre at KMC
IndiaChem
- 2004 to host concurrent pharma exhibition in Mumbai
City to
host conference on global bio pharma
ANNOUNCEMENT |
DBT
to organise national consultations on Biosafety
NPPA
revises prices
|
|
NANOMEDICINE
|
CONVERSATION
|
Global
developments and growth opportunities
NANOTECHNOLOGY holds the promise
to unleash a whole new era in a variety of areas that
include chemicals and materials, electronics, computing
and of course, medicine. |
‘Peptides
have potency to treat several types of cancer’
Hyderabad-based Issar Pharmaceuticals Pvt Ltd — a
company involved in research, development and commercialisation
of peptides and peptide-based pharmaceutical formulations
— has pioneered the first peptide derived product
‘Melgain’ for treatment of Vitiligo, commonly
known as leucoderma. |
|
PRODUCTS
|
|
|
